OCTP Stock Overview A pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Oxford Cannabinoid Technologies Holdings Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Oxford Cannabinoid Technologies Holdings Historical stock prices Current Share Price UK£0.0011 52 Week High UK£0.014 52 Week Low UK£0.00075 Beta 0.82 1 Month Change -67.14% 3 Month Change -73.26% 1 Year Change -89.78% 3 Year Change -97.39% 5 Year Change n/a Change since IPO -97.70%
Recent News & Updates Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official List May 09
New minor risk - Shareholder dilution Mar 04 Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024 Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Feb 15
New major risk - Share price stability Jan 31
Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 23 See more updates Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official List May 09
New minor risk - Shareholder dilution Mar 04 Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024 Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Feb 15
New major risk - Share price stability Jan 31
Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 23
New minor risk - Financial data availability Jan 15
Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2 Jan 10
Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive Director Nov 15
Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201 Oct 10
New major risk - Share price stability Oct 08
Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical Trial Sep 25
Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023 Aug 31
Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023 Aug 22
New major risk - Financial data availability Jul 26
Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer Malignancies Jul 18
Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical Officer Jun 09
Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial Application May 19
Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company Secretary Jan 16
Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201 Jan 06
Oxford Cannabinoid Technologies Holdings plc Announces Executive Changes Dec 05
Less than half of directors are independent Nov 16
Oxford Cannabinoid Technologies Holdings plc Announces Management Changes Oct 17
Karen Lowe to Step Down as Group Finance Director of Oxford Cannabinoid Technologies Holdings plc Aug 26
Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2022 Jul 25
Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2022 Results on Jul 25, 2022 Jul 20
Less than half of directors are independent Apr 27
Oxford Cannabinoid Technologies Holdings Plc Announces Formation of Scientific Advisory Board Apr 26
Oxford Cannabinoid Technologies Holdings plc Announces Updates on Lead Programme 1 and Programme 2 Apr 01 Oxford Cannabinoid Technologies Holdings plc Announces Data from Pre-Clinical Study of OCT461201 Shows Positive Results Mar 10
Oxford Cannabinoid Receives a Letter from GHS Capital Limited Feb 19
Oxford Cannabinoid Technologies Holdings plc Announces Board Changes Feb 01
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25 Shareholder Returns OCTP GB Pharmaceuticals GB Market 7D -32.4% -2.0% -2.2% 1Y -89.8% -3.5% 2.4%
See full shareholder returns
Return vs Market: OCTP underperformed the UK Market which returned 5.7% over the past year.
Price Volatility Is OCTP's price volatile compared to industry and market? OCTP volatility OCTP Average Weekly Movement 21.4% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: OCTP's share price has been volatile over the past 3 months.
Volatility Over Time: OCTP's weekly volatility has increased from 14% to 21% over the past year.
About the Company Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.
Show more Oxford Cannabinoid Technologies Holdings Plc Fundamentals Summary How do Oxford Cannabinoid Technologies Holdings's earnings and revenue compare to its market cap? OCTP fundamental statistics Market cap UK£1.25m Earnings (TTM ) -UK£4.24m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OCTP income statement (TTM ) Revenue UK£0 Cost of Revenue UK£2.33m Gross Profit -UK£2.33m Other Expenses UK£1.91m Earnings -UK£4.24m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/06/06 22:57 End of Day Share Price 2024/06/06 00:00 Earnings 2023/10/31 Annual Earnings 2023/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oxford Cannabinoid Technologies Holdings Plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Soo Romanoff Edison Investment Research
Show 0 more analysts 
